Instructions for Usage of Proteins

The pipeline from massive-scale protein production to delicate handling requires meticulous synchronization. By internalizing these guidelines, you can drastically mitigate assay interference, preserve sensitive molecular targets, and ensure robust, reproducible data output across all downstream biological and biophysical platforms.

Explore Biorbyt's Recombinant Proteins

Reconstitution, Handling, and FAQs

Proper handling of lyophilized proteins is the most critical step in ensuring assay success. A single mistake during reconstitution can lead to irreversible denaturation or catastrophic sample loss.

Q: When I opened the vial, I didn't see anything. Is it empty?
Always centrifuge the vial prior to opening. Most recombinant proteins are lyophilized in a low-concentration buffer, making the few micrograms of protein invisible to the naked eye. Spin the vial in a microcentrifuge for 20–30 seconds to ensure all material is safely gathered at the bottom of the tube before opening.

Q: What is the ideal concentration for reconstituting a lyophilized protein?
Reconstitution to a concentration between 0.1 mg/mL and 1.0 mg/mL is highly recommended. Avoid over-diluting the protein (e.g., < 0.1 mg/mL) during this initial step, as highly dilute proteins are extremely prone to structural instability and surface adsorption.

Q: What is a carrier protein and why is it necessary?
Proteins readily adsorb to the hydrophobic surfaces of standard polypropylene storage tubes, leading to significant sample loss and reduced assay activity. Carrier proteins, such as highly purified Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) added at 1–5 mg/mL (0.1–0.5%), prevent this by competitively pre-blocking the binding sites on the plastic. Always dilute active proteins in a buffer containing a recommended carrier protein before creating frozen aliquots.

Q: What does "CF" mean?
"CF" stands for Carrier-Free. While most commercial proteins include a carrier like BSA to enhance stability, the CF version omits it. Carrier-free proteins are strictly necessary for in vivo applications, direct protein labeling protocols, or structural assays where the overwhelming mass of BSA would cause signal interference.

Q: My reconstituted protein is spontaneously aggregating. How do I troubleshoot this?
Protein precipitation is usually caused by electrostatic interactions or exposed hydrophobic patches. To troubleshoot:

• Ensure your buffer pH is strictly maintained at least 1.0 pH unit above or below the protein's isoelectric point (pI).
• Add biochemical grade osmolytes and solubilizers (e.g., an equimolar mixture of L-Arginine and L-Glutamate at 50 mM each) to your buffer. This combination binds charged regions and dramatically boosts solubility.
• Include osmolytes like glycerol (5%) or sub-denaturing concentrations of non-ionic detergents (e.g., Tween-20 or Triton X-100) to shield hydrophobic patches.

Protein Storage and Shelf Life

Optimal storage conditions are distinct to each protein, but these general guidelines ensure stability and structural integrity over time.

Converting Biological Activity

The ED₅₀ designates the concentration required to induce 50% of the maximum biological response in a cell-based assay. To translate this into universally comparable, mass-independent units, use this standard conversion formula:

Recombinant Protein Expression Systems

Choosing an expression host permanently defines a protein's physical architecture, glycosylation profile, and biological viability.

• Prokaryotic (Escherichia coli): The standard for rapid, high-yield, and cost-effective production. Ideal for structurally simple proteins. However, E. coli lacks eukaryotic folding chaperones and post-translational modification (PTM) machinery. Complex mammalian targets often misfold into insoluble inclusion bodies.
• Yeast (S. cerevisiae, P. pastoris): Offers rapid growth and eukaryotic folding pathways. However, yeast utilizes high-mannose glycosylation, which differs significantly from human profiles and can trigger immunogenic responses.
• Insect Cells (Baculovirus): Excellent for large, multi-domain complexes. Produces paucimannose N-glycans but generally cannot synthesize the terminally sialylated structures required for human therapeutics.
• Mammalian Cells (CHO, HEK293): The absolute gold standard for complex biopharmaceuticals and functional transmembrane proteins. They execute human-like, terminally sialylated complex glycosylation, which is vital for protein stability, solubility, and native receptor binding.

Biorbyt Custom Services Overview

Biorbyt offers a comprehensive, highly scalable suite of custom services to support advanced discovery workflows. Whether you need challenging transmembrane proteins, specialized antibodies, or complex peptides, our team is equipped to deliver:

1. Custom Recombinant Protein Expression: Competitive large-scale production (10 mg to 200 mg) at >85% purity across 39 different expression tags. Complimentary services include desalination, endotoxin elimination, and aseptic processing.
   Request Protein Expression
2. Full-Length Membrane & ECD Expression: Utilizes 7 specialized platforms in high-density HEK293 systems to prevent the misfolding of difficult transmembrane targets, including Extra Cellular Domain (ECD) expression, Synthetic Nanodiscs, and PeptiNanodiscs.
   Explore Membrane Expression
3. Custom Recombinant Antibodies: Cloned into mammalian or bacterial expression vectors to ensure high specificity, infinite customization, and reduced animal use. Delivers 100 µg of purified antibody with ELISA/WB validation in 12–16 weeks.
   Discover Custom Antibodies
4. Custom Peptide Synthesis: Synthesis for peptides up to 100 amino acids long, delivered lyophilized at >95% purity. Includes complex modifications like D-amino acid incorporation, stable-isotope labeling, and PEGylation.
   Start Peptide Synthesis